Did Tapimmune Inc Make Bullish Trade After Eastern Capital Ltd increased Its Position?

May 16, 2018 - By Margaret Guttierez

TapImmune, Inc. (NASDAQ:TPIV) Corporate Logo

The increased Interest in Tapimmune Inc was posted by Eastern Capital Ltd

Eastern Capital Ltd filed with SEC a SC 13D/A form about Tapimmune Inc. The form can be accessed here: 000140840818000005.The filler increased its position in the stock by 24.53 % for 5,300,002 shares.In another form on May14, 2018 the percentage Eastern Capital Ltd has in stock is 38.8%.

And that’s Why Eastern Capital Ltd Holds Tapimmune Inc

Item 4.Purpose of Transaction

On May 14, 2018, Eastern CapitalLimited entered into a Common Stock Purchase Agreement with the Issuer to purchase 1,300,000 shares of common stock at a priceper share of $2.40.

The Reporting Persons acquiredthe Issuer’s securities for investment purposes.

The Reporting Persons currentlyhave no plans or proposals which relate to or would result in any transaction, event or action enumerated in paragraphs (a) through(j) of Item 4 of Schedule 13D.

CUSIP No. 876033408 Page 6 of 8

TPIV is reaching $3.26 during the last trading session, after increased 7.59%.TapImmune, Inc. has 153,209 shares volume, 262.58% up from normal. TPIV is downtrending and has moved 26.26% since May 17, 2017. The stock underperformed the S&P500 by 37.81%.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease.The firm is valued at $34.64 million. It specializes in the development of immunotherapies targeting women's cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers.Last it reported negative earnings. The company's peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

For more TapImmune, Inc. (NASDAQ:TPIV) news published recently go to: Prnewswire.com, Prnewswire.com, Benzinga.com, Prnewswire.com or Prnewswire.com. The titles are as follows: “TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno …” published on May 15, 2018, “TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference” on May 01, 2018, “32 Stocks Moving In Tuesday’s Mid-Day Session” with a publish date: May 01, 2018, “TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform” and the last “TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics” with publication date: May 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: